Stockscreener 앱 받기
28.18
1.07%
-0.305
전일 마감가:
$28.48
열려 있는:
$28.48
하루 거래량:
2.22M
Relative Volume:
0.36
시가총액:
$20.16B
수익:
$13.31M
순이익/손실:
$-1.01B
주가수익비율:
-24.11
EPS:
-1.1685
순현금흐름:
$-766.86M
1주 성능:
-0.55%
1개월 성능:
-5.13%
6개월 성능:
+75.65%
1년 성능:
+191.97%
1일 변동 폭
$27.95
$28.54
1주일 범위
$27.40
$28.78
52주 변동 폭
$9.57
$30.33
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
28.18 | 20.38B | 13.31M | -1.01B | -766.86M | -1.1685 |
VRTX
Vertex Pharmaceuticals Inc
|
437.29 | 113.64B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
747.90 | 81.18B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.07 | 49.78B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 42.87B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
309.60 | 34.79B | 5.36B | 287.73M | 924.18M | 2.5229 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-20 | 개시 | Bernstein | Outperform |
| 2025-09-02 | 개시 | Citigroup | Buy |
| 2025-07-10 | 재개 | Goldman | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2024-01-05 | 개시 | Piper Sandler | Overweight |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-17 | 개시 | Guggenheim | Buy |
| 2023-06-08 | 개시 | BofA Securities | Neutral |
| 2022-10-27 | 개시 | JP Morgan | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-12-15 | 개시 | Goldman | Buy |
| 2021-11-08 | 개시 | H.C. Wainwright | Buy |
| 2021-10-28 | 개시 | Citigroup | Buy |
| 2021-10-26 | 개시 | Cowen | Outperform |
| 2021-10-26 | 개시 | Jefferies | Buy |
| 2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Analysts Are Bullish on Top Healthcare Stocks: Roivant Sciences (ROIV), Boston Scientific (BSX) - The Globe and Mail
Roivant Sciences Ltd. (ROIV) Stock forecasts - Yahoo Finance UK
Capricorn Fund Managers Ltd Buys 247,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data UpdateSlideshow (NASDAQ:ROIV) 2026-04-04 - Seeking Alpha
ROIV PE Ratio & Valuation, Is ROIV Overvalued - Intellectia AI
ROIV | Roivant Sciences Ltd. Common Executive Compensation - Quiver Quantitative
Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial UpdatesHas The Bull Case Changed? - simplywall.st
Roivant Sciences Ltd. (ROIV) stock price, news, quote and history - Yahoo Finance UK
Roivant Sciences Ltd. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Should Brepocitinib’s New Trials and Batoclimab’s Setback Require Action From Roivant Sciences (ROIV) Investors? - Yahoo Finance
Roivant (NASDAQ: ROIV) executive settles RSU taxes with shares - Stock Titan
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP - Yahoo Finance
Roivant Shrugs Off Batoclimab Phase III Failure in TED - Citeline News & Insights
Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint - Yahoo Finance
Roivant (Nasdaq: ROIV) shows $4.3B cash and mixed late-stage trial results - Stock Titan
Scarring hair-loss disease gets drug trial with no approved therapy - Stock Titan
Roivant Sciences (ROIV) executive settles CVARs and RSUs into shares - Stock Titan
Roivant Sciences Ltd. (ROIV) Stock Forecasts - Yahoo Finance
(ROIV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Movement Recap: Is Roivant Sciences Ltd forming a bullish divergence2026 Patterns & Long-Term Capital Growth Strategies - baoquankhu1.vn
CEO Change: Is Roivant Sciences Ltd a potential multi bagger2026 Pullbacks & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Volume Summary: Is Roivant Sciences Ltd stock risky to hold now2026 Retail & Community Consensus Stock Picks - baoquankhu1.vn
250,468 Shares in Roivant Sciences Ltd. $ROIV Acquired by Exchange Traded Concepts LLC - MarketBeat
Roivant Sciences Insider Sold Shares Worth $1,921,500, According to a Recent SEC Filing - MarketScreener
Roivant Sciences Ltd (ROIV) Stock Price Quote Today & Current Price Chart - Capital.com
Roivant Sciences Ltd (ROIV) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Roivant Sciences (NASDAQ: ROIV) director exercises 70K options, sells 70K shares - Stock Titan
Aug Sentiment: Is Roivant Sciences Ltd backed by strong institutional buyingStock Surge & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success - Sahm
Cantor Fitzgerald reiterates Roivant Sciences stock rating By Investing.com - Investing.com India
Gains Recap: Should I hold or sell Roivant Sciences Ltd nowMarket Weekly Review & AI Driven Stock Movement Reports - baoquankhu1.vn
Sentiment Watch: Is Roivant Sciences Ltd a potential multi bagger2026 Decliners & High Accuracy Swing Entry Alerts - baoquankhu1.vn
ROIV Technical Analysis & Stock Price Forecast - Intellectia AI
Bernstein initiates coverage of Roivant Sciences Ltd. (ROIV) with an outperform rating - msn.com
New England Journal of Medicine publishes positive phase 3 valor trial results of brepocitinib in dermatomyositis - marketscreener.com
NEJM study: rare muscle-skin disease drug beat placebo in Phase 3 - Stock Titan
Aug Ideas: Whats the fair value of Roivant Sciences Ltd stockTrade Exit Report & Community Verified Watchlist Alerts - baoquankhu1.vn
Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)? - simplywall.st
Can Roivant Sciences Ltd sustain earnings growthEarnings Performance Report & AI Forecasted Stock Moves - baoquankhu1.vn
Big Money Moves: Can Roivant Sciences Ltd sustain earnings growthProduct Launch & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Vanguard realignment leads to separate reports for Roivant (ROIV) - Stock Titan
Bernstein Initiates Coverage of Roivant Sciences Ltd. (ROIV) with an Outperform Rating - Insider Monkey
Roivant Sciences (ROIV) CFO reports RSU tax-withholding of 1,546 shares - Stock Titan
Assenagon Asset Management S.A. Purchases 6,877,348 Shares of Roivant Sciences Ltd. $ROIV - marketbeat.com
Roivant Sciences, Genevant, Arbutus, and Moderna Settle International Patent Litigation – Key Terms and Confidentiality Details - Minichart
Roivant Sciences (ROIV) soars 19.4% as pipeline drugs progress - MSN
Roivant secures FDA priority review for dermatomyositis treatment - MSN
Risk Analysis: Is Roivant Sciences Ltd backed by strong institutional buyingBreakout Watch & High Conviction Investment Ideas - baoquankhu1.vn
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
(ROIV) Risk Channels and Responsive Allocation - Stock Traders Daily
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Roivant Sciences Ltd 주식 (ROIV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Fitzgerald Meghan | Director |
Mar 26 '26 |
Option Exercise |
8.80 |
70,000 |
616,000 |
112,963 |
| Fitzgerald Meghan | Director |
Mar 26 '26 |
Sale |
27.45 |
70,000 |
1,921,500 |
42,963 |
0.80%
0.41%
자본화:
|
볼륨(24시간):